Browse by author
Lookup NU author(s): Professor David KavanaghORCiD, Professor Tim Goodship
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Atypical hemolytic uremic syndrome (aHUS) is a disease characterized by over-activation of complement. Recurrence following renal transplantation is determined by a genetic predisposition. Genetic screening of all individuals with aHUS should be performed prior to listing for transplantation. Individuals with isolated mutations in MCP have a low risk of recurrence and may be considered for kidney transplantation alone. In individuals with CFH and CFI mutations, the risk of recurrence following renal transplantation is high. Combined liver/kidney transplantation has been used successfully in individuals with CFH mutations following the introduction of perioperative plasma exchange; however, such a procedure is not without its risks. Liver/kidney transplantation has yet to be performed on individuals with CFI and C3 mutations but may be predicted to be successful. In individuals with CFH autoantibodies, a reduction in titer through plasma exchange and rituximab has been successful. Clinical trials of the complement C5 inhibitor eculizumab may improve prospects for isolated renal transplantation in individuals with complement protein mutations.
Author(s): Kavanagh D, Richards A, Goodship T, Jalanko H
Publication type: Article
Publication status: Published
Journal: Seminars in Thrombosis and Hemostasis
Year: 2010
Volume: 36
Issue: 6
Pages: 653-659
Print publication date: 01/09/2010
ISSN (print): 0094-6176
ISSN (electronic): 1098-9064
Publisher: Thieme Medical Publishers
URL: http://dx.doi.org/10.1055/s-0030-1262887
DOI: 10.1055/s-0030-1262887
Altmetrics provided by Altmetric
